Skip to main content
Company profile
uniQure N.V. logo

uniQure N.V.

Pipeline5 assets

  • AMT-130AMT-130 / Huntingtin protein (mHTT) / Gene Therapy (AAV5) / Central Nervous System
    Huntington's DiseasePhase 1/2ActiveGlobal
  • AMT-191AMT-191 / Alpha-galactosidase A (GLA) / Gene Therapy / Rare Diseases
    Fabry DiseasePhase 1/2aActiveGlobal
  • AMT-260AMT-260 / Undisclosed / Gene Therapy / Central Nervous System
    Refractory Mesial Temporal Lobe EpilepsyPhase 1/2aActiveGlobal
  • AMT-162AMT-162 / SOD1 / Gene Therapy / Central Nervous System
    Amyotrophic Lateral Sclerosis (ALS)Preclinical/ClinicalActiveGlobal
  • etranacogene dezaparvovecAMT-061 / HEMGENIX / Factor IX / Gene Therapy (AAV5) / Hematology
    Hemophilia BApprovedMarketedUSGlobal

Latest news12 items

All news

uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression

~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression (non-significant p=0.144) and TFC showed a 61% slowing of

Trial Results • Phase 1/2Results call Tue, Sep 29, 2026, 8:30 AM ET

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected in September 2026 ~ ~ Reported data from the first cohort in the Phase I/IIa trial of AMT-260 for

Trial Results • Phase 1/2AMT-130 Phase I/II four-year topline data Tue, Sep 1, 2026

uniQure to Announce Second Quarter 2026 Financial Results

~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, July 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second

uniQure Announces Pricing of Upsized $225 Million Public Offering

LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 4,945,055

uniQure Announces $150 Million Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $150 million underwritten public offering of its ordinary

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~ LEXINGTON, Mass. and AMSTERDAM, June 19, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing

Interim Data • Phase 1/2Epilepsy Foundation Pipeline Conference presentation Fri, Jun 19, 2026

uniQure to Announce First Quarter 2026 Financial Results

~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, April 28, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first

uniQure N.V. • Endpoint Arena